FORM 4

UNITED STATES SECU

Washington, D.C. 20549

| KIII | ES ANL | EXCHA | NGE C | OMMISSIC | JN |
|------|--------|-------|-------|----------|----|
|------|--------|-------|-------|----------|----|

| | OMB APPROVAL | | | | | | | | | |
|---|--------------|-----------|--|--|--|--|--|--|--|--|
| Ĭ | OMB Number: | 3235-0287 | | | | | | | | |

0.5

See Note

2(2) See Note

2(2)

Estimated average burden

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a crieck this both inlineate that the account of the pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* <u>Mathers Edward T</u> | | | | 2. Issuer Name and Ticker or Trading Symbol MBX Biosciences, Inc. [MBX] | | | | | | tionship of Reporting all applicable) Director | Person(s) to Iss | | |
|--|---------------|----------------|--|---|--------------------------|-----------|------------------------------------|-------|------------------------------------|---|---|---|--|
| (Last) 104 5TH AVE 19TH FLOOR | (First) | (Middle) | 3. Date 09/16/2 | of Earliest Transact 2024 | ion (Mo | nth/Da | ay/Year) | | | Officer (give title below) | Other below | (specify) | |
| (Street) NEW YORK (City) | NY (State) | 10011 (Zip) | 4. If Am | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | |
| Date | | | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | Transaction Code (Instr. | | 4. Securities Ad Disposed Of (D | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership | |
| | | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (Instr. 4) | | |
| Common Stock 09/ | | 09/16/2024 | | С | | 1,023,103 | A | (1) | 1,023,103 | I | See Note 2 ⁽²⁾ | | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

C

2,091,383

500,000

A

\$16

| | (0.5, pane, oane, narrane, opnone, contention) | | | | | | | | | | | | | | |
|---|---|--|---|------------------------------|---|------------|------------|--|--------------------|--|----------------------------------|---|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | Derivative | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | Transaction(s) (Instr. 4) | | |
| Series A Convertible Preferred Stock | (1) | 09/16/2024 | | С | | | 12,299,854 | (1) | (1) | Common Stock | 1,023,103 | (1) | 0 | I | See Note 2 ⁽²⁾ |
| Series B Convertible Preferred Stock | (1) | 09/16/2024 | | С | | | 25,142,840 | (1) | (1) | Common Stock | 2,091,383 | (1) | 0 | I | See Note 2 ⁽²⁾ |

Explanation of Responses:

Common Stock

Common Stock

- 1. Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.
- 2. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

/s/ Zachary Bambach, attorneyin-fact ** Signature of Reporting Person

09/17/2024

Date

3,114,486

3,614,486

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

09/16/2024

09/16/2024

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.